Drug Delivery News and Research

RSS

Drug delivery is a term that refers to the delivery of a pharmaceutical compound into the body. Most common methods of delivery include the preferred non-invasive oral (through the mouth), nasal, pneumonial (inhalation), and rectal routes. Much research is now focussing on nanotechnology as a drug delivery method.

MicroStockProfit.com releases NexMed investment report

MicroStockProfit.com announces an investment report featuring NexMed Inc.. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

7 May 2010

Intellipharmaceutics generic Effexor XR ANDA accepted for filing by the FDA

Intellipharmaceutics International Inc., today announced that the Food and Drug Administration (FDA) has accepted for filing its abbreviated new drug application (ANDA) for a generic version of the antidepressant Effexor XR® (venlafaxine hydrochloride).

7 May 2010

Merrion Pharmaceuticals increases patent protection for Orazol

Merrion Pharmaceuticals plc, a pharmaceutical development company, today announces that it has been granted a further U.S. Patent, increasing the protection for their lead product, Orazol™.

7 May 2010

Genzyme to initiate $2 billion stock buyback

Genzyme Corp. today announced that its Board of Directors has voted to pursue several actions to increase shareholder value. The company will initiate a $2 billion stock buyback, under which $1 billion of stock will be repurchased in the near term and financed with debt. The additional $1 billion of stock will be repurchased during the next 12 months.

7 May 2010

Oramed reports Phase 2b non-FDA clinical trial results of ORMD-0801 oral insulin capsule

Oramed Pharmaceuticals Inc., a developer of alternative drug delivery systems, reported today results for the recently completed Phase 2b non-FDA clinical trial of its flagship oral insulin capsule, ORMD-0801.

7 May 2010

SCOLR Pharma grants RedHill worldwide rights to market and sell CDT-based ondansetron

SCOLR Pharma, Inc. today announced that it has executed a Licensing Agreement with RedHill Biopharma Ltd. an Israeli corporation, (RedHill), granting RedHill the worldwide rights to market and sell ondansetron tablet formulations based on SCOLR's proprietary extended delivery technology (CDT). Ondansetron hydrochloride is the active ingredient in Zofran®, GlaxoSmithKline's drug to prevent chemotherapy and radiation related nausea and vomiting.

6 May 2010

Alexza Pharmaceuticals secures $15M working capital loan from Hercules Technology Growth Capital

Alexza Pharmaceuticals, Inc. announced today that it has executed a $15 million working capital loan agreement with Hercules Technology Growth Capital. The funds available under the loan will be used for capital equipment and working capital purposes. In connection with the loan, Alexza issued Hercules warrants to purchase 376,394 shares of common stock at an exercise price of $2.69 per share, which was the 50-day average daily weighted average trading price at the time the term sheet for the loan was issued by Hercules.

6 May 2010

CPEX Pharmaceuticals reports record quarterly royalty revenues from Testim sales

CPEX Pharmaceuticals, Inc. today reported financial results for the first quarter ended March 31, 2010. For the quarter CPEX reported revenues of $5.3 million and a net loss of $940,000.

5 May 2010

Cryo-EM images shed light on virus structure, function

UCLA researchers report in the April 30 edition of the journal Cell that they have imaged a virus structure at a resolution high enough to effectively "see" atoms, the first published instance of imaging biological complexes at such a resolution.

5 May 2010

Particle Sciences extends collaboration with Microfluidics to implement MRT system

Particle Sciences and Microfluidics extended their collaboration with the placement of the newly-announced Microfluidics Reaction Technology system at Particle Sciences.

5 May 2010

Alexza Pharmaceuticals announces filing of universal shelf registration statement with SEC

Alexza Pharmaceuticals, Inc. announced today that it has filed a universal shelf registration statement with the Securities and Exchange Commission (SEC) that, if declared effective by the SEC, will allow the Company to sell, from time to time, up to $75 million of its common stock, preferred stock, debt securities and/or warrants, either individually or in units, in one or more offerings.

5 May 2010

IBI to present data on Verisome Liquid Drug Delivery System for cystoid macular edema at ARVO 2010

Icon Bioscience, Inc., (IBI), a privately held biopharmaceutical company that specializes in the development and commercialization of novel ophthalmic pharmaceuticals announced today that it will present an abstract demonstrating the utility of its Verisome™ Liquid Drug Delivery System in cystoid macular edema, at the Association for Research in Vision and Ophthalmology (ARVO) 2010 annual meeting, taking place May 2-6, 2010, in Fort Lauderdale, Florida.

5 May 2010

Cambrex first-quarter sales down 6.4% to $56.2 million

Cambrex Corporation reports first quarter results for the period ended March 31, 2010.

4 May 2010

Generic Flomax launch drives Impax Laboratories first-quarter total revenue to $323.3 million

Impax Laboratories, Inc. today reported significant growth in the first quarter of 2010 due to an increase in sales from its Global product sales channel. Total revenue increased $264.4 million to $323.3 million driven by the successful March 2 exclusive launch of generic Flomax® ($176.2 million of revenue and $167.9 million of gross profit) and continued strong sales of generic Adderall XR® for which there were no comparable amounts in the first quarter 2009, as well as increased sales of the Company's fenofibrate products.

4 May 2010

Celsion reports $4.6 million net loss from operations for first-quarter 2010

Celsion Corporation, a leading oncology drug development company, announced today financial results for the first quarter ended March 31, 2010 and addressed the progression of the clinical trials of ThermoDox®, Celsion's heat activated liposomal encapsulation of doxorubicin. ThermoDox® is currently being evaluated in the Phase III HEAT trial for the treatment of hepatocellular carcinoma (HCC) and in a Phase I/II trial for patients with recurrent chest wall breast cancer.

4 May 2010

JNM supplement examines advances in cardiovascular molecular imaging

The Journal of Nuclear Medicine -the top-rated medical imaging journal worldwide-has published Multimodality Molecular Imaging of the Cardiovascular System, presenting the state of the art of cardiovascular molecular imaging and discussing opportunities and challenges in advancing cardiovascular molecular imaging to clinical practice.

4 May 2010

Landec announces acquisition of Lifecore Biomedical from Warburg Pincus Private Equity

Landec Corporation, a materials science company that develops and markets patented polymer products for food, agriculture, personal care and drug delivery applications, today announced that it has acquired Lifecore Biomedical, Inc. from Warburg Pincus Private Equity IX, LP. When acquired by Warburg Pincus in March 2008, Lifecore was comprised of two divisions, the Dental Division and the Hyaluronan Division. The Dental Division was merged into a Warburg Pincus portfolio company.

3 May 2010

BioSante Pharmaceuticals reinitiates GVAX Prostate Cancer Vaccine development

BioSante Pharmaceuticals, Inc. today announced that development of its GVAX Prostate Cancer Vaccine (GVAX Prostate) for the treatment of prostate cancer has been reinitiated. Manufacturing of new GVAX Prostate is in process, regulatory steps to lift the GVAX Prostate clinical hold prior to trial initiation are being taken, and prostate cancer patients are expected to be treated in a Phase II human clinical trial beginning in the fourth quarter of 2010 at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center.

3 May 2010

Ethicon Endo-Surgery SEDASYS CAPS system receives European Union CE Mark, Health Canada approval

Ethicon Endo-Surgery today announced that the SEDASYS® System, the first computer-assisted personalized sedation (CAPS) system, was granted a CE Mark for the European Union for routine colonoscopy and screening of the upper gastrointestinal tract (EGD procedures), and Health Canada granted regulatory approval for the SEDASYS® System for use by healthcare professional teams during routine colonoscopy.

3 May 2010

Penwest Pharmaceuticals reports net income of $3.9 million for first-quarter 2010

Penwest Pharmaceuticals Co. today announced its financial results for the first quarter ended March 31, 2010. Compared with the first quarter of 2009, first quarter 2010 revenues increased sharply to $8.8 million, and operating expenses decreased by 20%. The Company had net income of $0.12 per share for the first quarter of 2010.

3 May 2010

Drug Delivery News and Research

Further Reading

MicroStockProfit.com releases NexMed investment report

Intellipharmaceutics generic Effexor XR ANDA accepted for filing by the FDA

Merrion Pharmaceuticals increases patent protection for Orazol

Genzyme to initiate $2 billion stock buyback

Oramed reports Phase 2b non-FDA clinical trial results of ORMD-0801 oral insulin capsule

SCOLR Pharma grants RedHill worldwide rights to market and sell CDT-based ondansetron

Alexza Pharmaceuticals secures $15M working capital loan from Hercules Technology Growth Capital

CPEX Pharmaceuticals reports record quarterly royalty revenues from Testim sales

Cryo-EM images shed light on virus structure, function

Particle Sciences extends collaboration with Microfluidics to implement MRT system

Alexza Pharmaceuticals announces filing of universal shelf registration statement with SEC

IBI to present data on Verisome Liquid Drug Delivery System for cystoid macular edema at ARVO 2010

Cambrex first-quarter sales down 6.4% to $56.2 million

Generic Flomax launch drives Impax Laboratories first-quarter total revenue to $323.3 million

Celsion reports $4.6 million net loss from operations for first-quarter 2010

JNM supplement examines advances in cardiovascular molecular imaging

Landec announces acquisition of Lifecore Biomedical from Warburg Pincus Private Equity

BioSante Pharmaceuticals reinitiates GVAX Prostate Cancer Vaccine development

Ethicon Endo-Surgery SEDASYS CAPS system receives European Union CE Mark, Health Canada approval

Penwest Pharmaceuticals reports net income of $3.9 million for first-quarter 2010

Drug Discovery - Second Edition eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News